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RISPR/Cas9 is a gene editing 
technology that is revolutionising the 
way that scientists design biomedical 
research. In addition to this, 
CRISPR/Cas9 is opening promising avenues for 
applications in gene therapy, manufacturing, and 
agriculture. The commercial and disruptive 
potential of this invention is so promising that it 
sparked a ‘gold rush’ towards patenting 
CRISPR/Cas technologies. Two principal 
players weighed in to define the CRISPR/Cas9 
patent landscape in the US: the University of 
California Berkeley (UCB) and the Broad 
Institute, a joint MIT-Harvard research institute 
[1]. This ultimately led to a high-profile patent 
battle in front of the US Patent Trial and Appeal 
Board, where the Broad Institute prevailed in the 
first instance [2]. The dispute, however, 
continues worldwide. In this Communication, I 
will focus on the European front of this litigation; 
the problem being not only who owns this 
technology in Europe, but also what are the 
potential impacts of patent conflicts between 
academic institutions on European policy and 
law. 
 
 
 
A song of CRISPR and Cas 
Others have more extensively narrated how a 
niche field of research, an ‘immune system’ 
found in bacteria, became the next big thing in 
genome editing [3,4]. CRISPR stands for 
‘clustered regularly interspaced palindromic 
repeats’ and describes a region in prokaryotic 
genomes where arrays of repeated near-
palindromic sequences—nucleic acid 
sequences, e.g. GACGTC, where the 
complementary strand (CTGCAG) is the 
mirrored image of the primary one—are 
interlaced with short variable sequences. 
Scientists first acknowledged the existence of 
such genomic patterns in the bacterium 
Escherichia coli in 1987, and in many other 
prokaryotes (either archaea or eubacteria) over 
the next decade. In the mid-2000s, multiple 
authors suggested that CRISPR acts as a 
‘bacterial adaptive immune system’ [3]. A few 
years later, multiple CRISPR-associated 
proteins (Cas) were described as effectors of 
this function in prokaryotes. Among Cas 
proteins, Cas9 has been characterised 
extensively from a biochemical and biological 
point of view. 
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At this point, one could use patents to tell the 
recent story of CRISPR/Cas9 systems. This 
approach might be less appealing than the 
(often controversial) ‘heroic’ narrative of 
CRISPR [3], but it also permits to avoid (cherry) 
picking which scientists provided major 
contributions towards understanding this system 
[4]. The players that are sectioning the patent 
landscape of CRISPR/Cas are also dividing a 
‘pie’ worth tens of millions of USD [1], but are 
not the only people who contributed to the 
science behind this technology. 
The first attempt at patenting CRISPR/Cas dates 
back to 2008 [5], when Luciano Marraffini and 
Erik J. Sontheimer from Northwestern University 
demonstrated that CRISPR/Cas could cut DNA 
– and could potentially be used to interrupt 
horizontal gene transfer from/to pathogens. The 
authors abandoned this patent due to a lack of 
sufficient experimental evidence; however, 
Marraffini would later become a key actor in the 
Broad/UCB patent battle in Europe. The first 
successful CRISPR patent application was filed 
by a Lithuanian researcher, Virginijus Šikšnys, in 
March 2012 [6]. This patent is, however, widely 
overlooked in most ensuing CRISPR patent 
battles as it contains claims on a CRISPR-RNA 
system created in vitro—not genetically encoded 
like the Broad/UCB one. 
Another fundamental patent application was filed 
in May 2012 [7]. It came from Jennifer Doudna, 
a structural biologist at UCB, and Emmanuelle 
Charpentier, who was at the time a 
microbiologist at Umeå University in Sweden. 
The collaboration of the teams led by the two 
women made it possible to engineer a 
CRISPR/Cas9 system to induce a targeted 
double-stranded DNA cleavage in vitro [8]. 
Figure 1 shows the mechanism of this DNA 
editing technology. The plot twist in this story 
was a patent filed by Feng Zhang at the Broad 
Institute in December 2012, that contained 
claims on a protocol to apply CRISPR/Cas9 
system for genome editing in eukaryotic cells [9]. 
Later on, his team published a study in Science, 
where they were able to edit the genome of 
murine and human cells [10].  With an expensive 
patent gamble, the Broad Institute collaboration 
fast-tracked its application to the US Patent and 
Trademark Office (USPTO) [1]; the patent was 
accepted in 2014, while the one from UCB is still 
pending. 
CRISPR Total War 
Both UCB and the Broad Institute claim an 
engineered CRISPR-Cas9 system for use in 
genome editing. Doudna and Charpentier’s 
patent does not specify the cell types to which it 
might be applied, while Zhang’s patent claims 
specific use on eukaryotic cells. If we represent 
the two patents as Venn diagrams, the claims of 
the latter patent might be a subset of the former. 
And to be patentable, an invention must be 
novel considering the information already 
available to the public (the ‘prior art’), show non-
obvious inventive step from already patented 
inventions, and it must be fully disclosed.  
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Figure 1 CRISPR-Cas9 mechanism. A) Cas9 
(orange) is a Cas protein with multiple functions: 
in nature it complexes with targeting RNA 
derived from a CRISPR cluster (crRNA) and a 
second, structural RNA called tracer RNA 
(tracRNA). The group from Doudan and 
Chaprentier proved that these two RNAs can 
replaced with a single guide RNA (sgRNA, 
magenta) [8]. B) The RNA-protein complex then 
unwinds the double helix and scans the genome 
until it reaches a sequence which 1) is 
complementary to the spacer region of crRNA 
and 2) is adjacent to a sequence motif called a 
PAM site. After sequence recognition, Cas9 
cleaves double-stranded DNA three bases 
upstream of the PAM sequence from both sides 
leaving blunt-ends, which are hotspots for 
homologous recombination (fundamental to 
gene knock-ins) or small sequence deletions 
that might lead to gene knock-out. Panel A from 
Streptococcus pyogenes Cas9 structure 
resolved with X-ray diffraction (PDB:4OO8). 
Panel B adapted by permission from Macmillan 
Publishers Ltd: Nat. Rev. Mol. Cell Biol, 
doi:10.1038/nrm.2015.2 © (2016).  
In 2016, UCB filed an interference to the USPTO 
stating that the Broad’s patent is an ‘obvious’ 
derivation from their own. This action opened a 
high-level international patent war between 
Cambridge (MA) and Berkeley. The focal point 
being whether it would be trivial to use the 
system developed in vitro by Doudna and 
Charpentier in eukaryotic cells. The Broad 
Institute managed to convince the US Patent 
Trial and Appeal Board that its patent is a non-
obvious application of the system patented by 
UCB [2]. The ruling opened a scenario in the US 
where both the UCB (when awarded) and Broad 
patents might be valid for commercial 
application in agriculture or human gene 
therapy. UCB has since filed an appeal to the 
decision of the USPTO, but their decision is still 
pending [2]. 
The war for CRISPR/Cas9 is not over yet, 
because each Regional/National Patent Office is 
a distinct battlefield. For example, in 2017 China 
took sides with Doudna and Charpentier, 
granting them a patent for the use of 
CRISPR/Cas9 in vitro and in all types of cells 
[2]. This came after the European Patent Office 
(EPO) also granted the two scientists a 
CRISPR/Cas9 patent with broad claims 
(EP2800811) in May of the same year. 
CRISPR goes to Crete  
When moving to the Old Continent, the dispute 
over CRISPR patents becomes labyrinthine, 
with no Ariadne’s thread in sight. Multiple 
players are in the arena, along with Doudna and 
Charpentier, and Zhang. Some are to be 
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expected—such as Vilnius University, the home 
institution of Virginijus Šikšnys, inventor of a 
non-genetically encoded CRISPR technology—
others are not. Of note is Merck’s subsidiary 
company MilliporeSigma, which was granted a 
patent for a CRISPR-based knock-in strategy 
specific for genome editing in eukaryotic cells 
(EP3138910). EPO’s decision caused surprise 
among American commentators [11]. 
MilliporeSigma’s patent—also granted in 
Australia, Singapore, and Canada—covers 
claims very similar to those presented by the 
Broad Institute [10], but was filed six days prior.    
The EPO awarded the European equivalent of 
the patent at the centre of the American dispute 
to the Broad Institute back in 2015 (EP2771468) 
following an international patent application 
naming the Broad Institute, MIT and Harvard as 
applicants. The application was filed in 
December 2013 claiming a priority date of 
December 2012—i.e. the date the patent was 
first filed to the USPTO [12]. Claiming priority 
means that the novelty of the patent is to be 
established as if it were filed on the priority date 
(December 2012), and not on the filing date 
(December 2013) [13]. In this story, dates are as 
fundamental as reading. 
Opponents of the Broad Institute’s patent in 
Europe have found a winning argument, based 
on a technical difference between European and 
US patent law, which led to the revocation of the 
patent on 17th January 2018. One of the priority 
documents, dated 2012 (US application 
61736527), named Luciano Marraffini, at the 
time at Rockefeller University in New York, as 
co-inventor with Zhang, while the application 
included only the latter as inventor. This 
mismatch is not coming out of the blue, but is 
the result of a non-conventional parallel patent 
dispute between Broad Institute and Rockefeller 
University, solved through arbitration in January 
2018 [14]. According to European rules, the 
names of inventors listed on priority documents 
and on the filed application must be identical in 
order to claim priority (in the US, at least one of 
the inventors must be present in both 
documents). This technicality meant that the 
application could not claim priority date and its 
effective date became the filing date. The Broad 
application lacked novelty over the prior art in 
December 2013 (see for example [10]) and 
ultimately had to be revoked.   
The Broad Institute is appealing the decision on 
the grounds that the EPO has rules contradicting 
international patent treaties. However, it is 
unlikely that the EPO is going to defy decades of 
patent case law to accommodate Broad’s 
requests [13]. Nonetheless, this revocation does 
not directly affect the many follow-up CRISPR 
patents that the Institute still holds in Europe. 
Thus, at the moment multiple institutions are in 
possession of key patents with similar claims on 
CRISPR/Cas9 in Europe. This situation is 
probably not going to have a winner-take-all 
solution, and it is likely that multiple players will 
share rights to the technology [13].  
CRISPR patents, academia, and policy making 
The CRISPR patent war is not just a fascinating 
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story for people interested in Intellectual 
Property law. At its core, there are fundamental 
issues related to the role of academic institutions 
in the commercialisation of their research, the 
consequences of ‘academia becoming business’ 
[1, 2, 15, 16], and the role of policy makers in 
addressing this issue (if need be).  
Patents are a contract between inventors and 
society, where one side discloses their invention 
to the public, and the other grants them the 
negative right to protect the invention for a 
definite period of time. This, in turn, incentivises 
people to create new tools or processes that 
might benefit society as a whole; patents serve 
as a powerful tool to drive scientific innovation. 
The link between legal protection of inventions 
and innovation has been recognised for a long 
time, for example the United States 
Constitutional Convention introduced an 
‘Intellectual Property clause’ in the U.S. 
Constitution (Article I, Section 8, Clause 8) as 
early as 1787. 
However, advantages become less clear when 
academic institutions are pushed towards 
patenting—or rather, exclusive licensing—and 
commercialising their research. The CRISPR 
patent dispute is defining a quite unprecedented 
scenario where a plethora of (mostly academic) 
players, each with partially overlapping claims 
on a technology, are present in different 
regional/national markets. One aspect of this 
problem is that universities, the patent owners, 
transfer licensing rights to their private 
‘commercial arms’ (a.k.a. spin-off companies) 
according to the practice of surrogate licensing 
[2, 15]. Compared with the past decades, this is 
a novel approach to the commercial exploitation 
of academic research [16] and it might be 
related to changes in the availability and 
distribution of research funding. Some scholars 
have warned that a convoluted licensing 
situation might end up hindering the 
development and commercial availability of 
CRISPR-derived biomedical technologies, since 
a handful of private companies would retain 
exclusive licensing rights to the technology [1, 
15].  
A second crucial point we need to focus on is 
the potentially detrimental effect that these 
litigations have on interinstitutional collaboration 
and on the way in which academic research is 
run. Again, the CRISPR example is 
paradigmatic, as it disclosed manual examples 
of toxic behaviours in academia: from 
downplaying the role of other groups in 
developing CRISPR/Cas9 [1], to using Prof. 
Doudna’s critical analysis of her own work as a 
key argument against UCB patent claims [2]. In 
the long run, the fear of patent clashes might 
hold back institutions from collaborating—in 
particular when potentially profitable 
technologies are on the table. This would betray 
one of the main assets of scientific research: 
collegiality. 
Funding bodies and policy makers might have a 
pivotal role in avoiding the emergence of a 
‘patent or perish’ culture in applied research. For 
instance, they could respectively adopt or 
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promote the adoption of evaluation criteria that 
would favour applicants providing forms of open 
licensing, such as patentleft (the patent 
analogue of copyleft), alongside standard ones. 
Another possibility is to encourage the use of 
patents to exert ways of ‘private governance’ [2] 
on their commercial derivations that would 
favour communities. For example, Monsanto’s 
license from the Broad Institute for agricultural 
applications of CRISPR/Cas9 requires the 
multinational company to allow the practice of 
saving and resewing seeds from one season to 
the next [17]. A policy-driven push on academic 
institutions towards open and ethical licensing, if 
matched with policies that encourage a fairer 
distribution of funding, might discourage 
research institutions from pursuing time- and 
money-intensive patent wars and put the focus 
back on openness and scientific collaboration.   
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